Amorfix and Aragen Bioscience enter into agreement to develop novel monoclonal antibodies for the treatment of cancers
"Fas receptor is a well characterized target on cells that, when activated, causes programmed cell death, or apoptosis. Previous attempts to use Fas receptor as a therapeutic target for the development of new anti-cancer therapeutics have failed because its expression and function lead to undesirable side effects on normal cells. Using our ProMIS(TM) technology, we have identified DSEs on Fas receptor that will provide the required specificity for our mAbs to target and kill tumor cells while leaving normal cells intact," said Dr. Robert Gundel , Vice President of Research and Development at Amorfix. "We are very pleased to be collaborating with Aragen Bioscience on this important project in hopes of generating a highly effective and safe new therapeutic for the treatment of a variety of cancers."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous